Project Grant R44DA059519
Award Date
9/15/24
Completion Date
8/31/27
Dollars Obligated
$1.1M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Wareham, MA 02571, USA
Similar Awards
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $304,023 Project Grant to Evidation Health, Inc. to develop a digital platform called "RESHAPE" that addresses health-related social needs (HRSN) impacting substance use disorder (SUD) recovery. The project aims to create a comprehensive digital experience that provides personalized education, insights, and support to improve the well-being and self-efficacy of...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $959,964 Project Grant to Charles River Analytics, Inc. to design and demonstrate the feasibility of a prototype system called "Stimulant Use Recovery via Immersive Virtual Environments (SURVIVE)" for the treatment of stimulant use disorder (STUD). The goal of SURVIVE is to leverage virtual reality technology to provide a convenient and engaging means of delivering...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...
The National Institute on Drug Abuse (NIDA) awarded a $326,410 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Berkshire Biomedical Corporation. The grant, which runs from June 1, 2025 to May 31, 2026, will fund a two-phased clinical study to evaluate the feasibility and efficacy of the Computerized Oral Prescription Administration System (COPA) - a hand-held, automated, personalized oral liquid dispensing system designed to deliver take-home methadone...
The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation (Boston Children's Hospital) to develop and pilot test a novel telehealth and mobile health intervention called MOMENT-V for treating cannabis use disorder in young adults. The intervention combines remote motivational enhancement therapy with ecological momentary interventions delivered via mobile app. The pilot...
This $591,032 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support the development of the "COGITO" digital therapeutics platform. COGITO is intended to provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics to prevent, treat, or manage a wide range of health conditions with behavioral components. The funding will be used to finalize key...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,607,146 Project Grant to Ndri-Usa Inc., a non-profit organization based in New York City. The grant, titled "TOGETHER AGAINST OVERDOSE: COMMUNITY DEVELOPED TECHNOLOGY TO ENCOURAGE DRUG CHECKING, DISTRIBUTION OF HARM REDUCTION SUPPLIES, AND LINKAGE TO SERVICES", aims to develop technology-based interventions to increase protective behaviors against overdose, such...
The National Institute on Drug Abuse (NIDA) awarded a $1,585,991 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Icahn School of Medicine at Mount Sinai in New York. The grant, awarded on May 1, 2025, will fund a double-blind randomized trial to evaluate the use of transcranial direct current stimulation (tDCS) combined with cognitive reappraisal training to reduce craving and cue-reactivity in individuals with cocaine use disorder. The study aims to explore...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development and pilot evaluation of a digital therapeutic called AMP-C. The goal of AMP-C is to address the comorbidity of cannabis use disorder (CUD) and major depressive disorder (MDD) by targeting reward dysfunction, a key shared mechanism underlying these co-occurring conditions. The $197,640 award to the General Hospital...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $319,278 Project Grant to Photopharmics, Inc. to develop a novel, non-pharmacological Heterodyned Whole Body Vibration (HWBV) device to treat Opioid Use Disorder (OUD). This 1-year Phase I award supports: 1) technical improvements to the HWBV device, evaluation of physiological anxiety indices, and implementation of device telemetry; 2) assessment of blood catecholamines and...